Literature DB >> 2237288

Cardiac amyloidosis: report of a patient heterozygous for the transthyretin isoleucine 122 variant.

M J Saraiva1, W Sherman, C Marboe, A Figueira, P Costa, A F de Freitas, M A Gawinowicz.   

Abstract

Amyloid fibril material was extracted from autopsy material of a patient who died from progressive cardiac failure at age 64. He had enlarged heart on routine X-ray at age 47 and the first symptoms of cardiac failure at age 62. Fractionation of the fibril material resolved peptide fragments immunoreactive with anti-human transthyretin (TTR). One of the peptides was further purified by high-performance liquid chromatography (HPLC) and subjected to tryptic peptide mapping along with TTR isolated from the patient's serum. In both instances, sequencing procedures revealed, in addition to the normal peptide 12 (residues 105-126), an abnormal peptide with an isoleucine for valine substitution at position 122. This substitution has been described previously in a patient with systemic senile amyloidosis (SSA) homozygous for this variant. The results question whether SSA is a clinical entity related to TTR Ile 122 with phenotypic expression in the homozygous condition.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2237288     DOI: 10.1111/j.1365-3083.1990.tb02928.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  10 in total

1.  Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein.

Authors:  Fredrik Noborn; Paul O'Callaghan; Erik Hermansson; Xiao Zhang; John B Ancsin; Ana M Damas; Ingrid Dacklin; Jenny Presto; Jan Johansson; Maria J Saraiva; Erik Lundgren; Robert Kisilevsky; Per Westermark; Jin-Ping Li
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

2.  Molecular analyses of an acidic transthyretin Asn 90 variant.

Authors:  M J Saraiva; M R Almeida; I L Alves; P Moreira; M Gawinowicz; P P Costa; S Rauh; A Banhzoff; K Altland
Journal:  Am J Hum Genet       Date:  1991-05       Impact factor: 11.025

3.  A new transthyretin mutation associated with amyloid cardiomyopathy.

Authors:  M J Saraiva; M do R Almeida; W Sherman; M Gawinowicz; P Costa; P P Costa; D S Goodman
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

4.  A specific test for transthyretin 122 (Val----Ile), based on PCR-primer-introduced restriction analysis (PCR-PIRA): confirmation of the gene frequency in blacks.

Authors:  D R Jacobson
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

Review 5.  Frequency and genetic background of the position 122 (Val----Ile) variant transthyretin gene in the black population.

Authors:  D R Jacobson; J D Reveille; J N Buxbaum
Journal:  Am J Hum Genet       Date:  1991-07       Impact factor: 11.025

6.  Transthyretin Ile 122 and cardiac amyloidosis in African-Americans. 2 case reports.

Authors:  D R Jacobson; M Ittmann; J N Buxbaum; R Wieczorek; P D Gorevic
Journal:  Tex Heart Inst J       Date:  1997

Review 7.  Amyloid in the cardiovascular system: a review.

Authors:  I Kholová; H W M Niessen
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

8.  Transthyretin Leu 68 in a form of cardiac amyloidosis.

Authors:  M R Almeida; A Hesse; A Steinmetz; B Maisch; K Altland; R P Linke; M A Gawinowicz; M J Saraiva
Journal:  Basic Res Cardiol       Date:  1991 Nov-Dec       Impact factor: 17.165

9.  Transthyretin Ser 6 gene frequency in individuals without amyloidosis.

Authors:  D R Jacobson; I L Alves; M J Saraiva; S N Thibodeau; J N Buxbaum
Journal:  Hum Genet       Date:  1995-03       Impact factor: 4.132

Review 10.  Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.

Authors:  Joel N Buxbaum; Frederick L Ruberg
Journal:  Genet Med       Date:  2017-01-19       Impact factor: 8.822

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.